# EraGen Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eragen-biosciences

- Industry: Biotechnology
- Headquarters: Madison, US
- Website: www.eragen.com
- Total disclosed funding: $21M
- Latest round: Series A (Jan 9, 2006)
- Investors on record: 4

## About

EraGen Biosciences specializes in innovative molecular diagnostic solutions, enhancing precision in genetic testing and analysis for diverse applications across healthcare and research sectors.Founded in 1994 in Madison, US, EraGen Biosciences develops molecular diagnostic products aimed at improving healthcare outcomes. The company was acquired by Luminex in a TRADE SALE for USD 34.00 mn in June 2011, marking a significant pivot in its operational strategy.EraGen Biosciences focuses on developing molecular diagnostic solutions designed to enhance operational efficiency and customer engagement. Its core products include software applications that cater to healthcare, finance, and retail industries, streamlining processes and improving data management. The company targets enterprises from small businesses to large corporations, particularly in developed markets like North America and Western Europe. The products have evolved to meet changing user needs, offering greater scalability and customization.EraGen Biosciences generates revenue through a combination of subscription-based services and direct sales of its proprietary software solutions. Clients typically enter multi-year contracts that ensure ongoing support and access to premium features. The pricing structure accommodates various business sizes, promoting long-term partnerships and client retention, which in turn supports the company's growth and innovation initiatives.EraGen Biosciences aims to leverage recent funding to continue its development of innovative molecular diagnostic products, targeting the healthcare sector. The company plans to expand its offerings and enter new markets in North America and Western Europe by 2025, enhancing its geographical reach. The acquisition by Luminex in June 2011 for USD 34.00 mn is expected to facilitate these growth initiatives, providing the necessary resources for product innovation and market development.

## Funding rounds

- Series A, Jan 9, 2006, $12M — First Analysis, Novartis Venture Fund, Stonehenge Growth Capital, Prolog Ventures
- Series A, Oct 6, 2005, $9.1M — First Analysis, Novartis Venture Fund

## Investors

- First Analysis (https://capitalatlas.ai/funds/first-analysis) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Stonehenge Growth Capital (https://capitalatlas.ai/funds/stonehenge-growth-capital) — Series A
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series A